ZA202001258B - Methods of using dantrolene to treat nerve agent exposure - Google Patents
Methods of using dantrolene to treat nerve agent exposureInfo
- Publication number
- ZA202001258B ZA202001258B ZA2020/01258A ZA202001258A ZA202001258B ZA 202001258 B ZA202001258 B ZA 202001258B ZA 2020/01258 A ZA2020/01258 A ZA 2020/01258A ZA 202001258 A ZA202001258 A ZA 202001258A ZA 202001258 B ZA202001258 B ZA 202001258B
- Authority
- ZA
- South Africa
- Prior art keywords
- dantrolene
- methods
- nerve agent
- agent exposure
- treat nerve
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762554049P | 2017-09-05 | 2017-09-05 | |
| US201862674406P | 2018-05-21 | 2018-05-21 | |
| PCT/US2018/049515 WO2019050923A1 (en) | 2017-09-05 | 2018-09-05 | METHODS OF USING DANTROLENE TO TREAT EXPOSURE TO A NEUROTOXIC AGENT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202001258B true ZA202001258B (en) | 2023-10-25 |
Family
ID=63708449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/01258A ZA202001258B (en) | 2017-09-05 | 2020-02-27 | Methods of using dantrolene to treat nerve agent exposure |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20200383954A1 (https=) |
| EP (1) | EP3678659B1 (https=) |
| JP (2) | JP2020532555A (https=) |
| KR (1) | KR20200047655A (https=) |
| CN (1) | CN111093652A (https=) |
| AU (1) | AU2018328131B2 (https=) |
| BR (1) | BR112020004429A2 (https=) |
| CA (1) | CA3074732A1 (https=) |
| IL (1) | IL272847B1 (https=) |
| MA (1) | MA50080A (https=) |
| MX (2) | MX2020002485A (https=) |
| SG (1) | SG11202001749SA (https=) |
| UA (1) | UA126688C2 (https=) |
| WO (1) | WO2019050923A1 (https=) |
| ZA (1) | ZA202001258B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022538608A (ja) * | 2019-06-28 | 2022-09-05 | ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア | アルツハイマー病の治療のための鼻腔内ダントロレン投与 |
| WO2023081873A1 (en) * | 2021-11-05 | 2023-05-11 | Quorum Innovations, Llc | Materials and methods for preventing or reducing toxicity to organophosphates and other toxic materials |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7758890B2 (en) * | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
| EP1603513B1 (en) * | 2003-03-04 | 2020-12-30 | Lyotropic Therapeutics, Inc. | Dantrolene compositions |
| WO2013040501A1 (en) * | 2011-09-16 | 2013-03-21 | Pharmathene, Inc. | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof |
| DK2925327T3 (da) * | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression |
-
2018
- 2018-09-05 UA UAA202002205A patent/UA126688C2/uk unknown
- 2018-09-05 BR BR112020004429-6A patent/BR112020004429A2/pt unknown
- 2018-09-05 JP JP2020512813A patent/JP2020532555A/ja active Pending
- 2018-09-05 MX MX2020002485A patent/MX2020002485A/es unknown
- 2018-09-05 US US16/644,281 patent/US20200383954A1/en not_active Abandoned
- 2018-09-05 WO PCT/US2018/049515 patent/WO2019050923A1/en not_active Ceased
- 2018-09-05 MA MA050080A patent/MA50080A/fr unknown
- 2018-09-05 KR KR1020207009450A patent/KR20200047655A/ko not_active Ceased
- 2018-09-05 EP EP18779490.4A patent/EP3678659B1/en active Active
- 2018-09-05 CA CA3074732A patent/CA3074732A1/en active Pending
- 2018-09-05 CN CN201880057290.XA patent/CN111093652A/zh active Pending
- 2018-09-05 AU AU2018328131A patent/AU2018328131B2/en active Active
- 2018-09-05 SG SG11202001749SA patent/SG11202001749SA/en unknown
-
2020
- 2020-02-23 IL IL272847A patent/IL272847B1/en unknown
- 2020-02-27 ZA ZA2020/01258A patent/ZA202001258B/en unknown
- 2020-03-04 MX MX2023012415A patent/MX2023012415A/es unknown
-
2021
- 2021-12-02 US US17/540,878 patent/US20220087980A1/en active Pending
-
2023
- 2023-01-27 JP JP2023010846A patent/JP2023055802A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023055802A (ja) | 2023-04-18 |
| EP3678659C0 (en) | 2025-12-17 |
| MX2020002485A (es) | 2020-07-20 |
| SG11202001749SA (en) | 2020-03-30 |
| BR112020004429A2 (pt) | 2020-10-20 |
| RU2020112318A (ru) | 2021-10-06 |
| NZ762056A (en) | 2025-10-31 |
| JP2020532555A (ja) | 2020-11-12 |
| AU2018328131B2 (en) | 2024-04-18 |
| US20200383954A1 (en) | 2020-12-10 |
| EP3678659A1 (en) | 2020-07-15 |
| UA126688C2 (uk) | 2023-01-11 |
| MA50080A (fr) | 2020-07-15 |
| IL272847B1 (en) | 2026-03-01 |
| MX2023012415A (es) | 2023-11-01 |
| CA3074732A1 (en) | 2019-03-14 |
| US20220087980A1 (en) | 2022-03-24 |
| AU2018328131A1 (en) | 2020-03-12 |
| RU2020112318A3 (https=) | 2021-10-26 |
| EP3678659B1 (en) | 2025-12-17 |
| CN111093652A (zh) | 2020-05-01 |
| IL272847A (en) | 2020-04-30 |
| WO2019050923A1 (en) | 2019-03-14 |
| KR20200047655A (ko) | 2020-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| MX2016017288A (es) | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer. | |
| MX2020005547A (es) | Moduladores de la actividad del complemento. | |
| MX2021009830A (es) | Metodos para el tratamiento de trastornos del movimiento involuntario anormal. | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
| MX385283B (es) | Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control. | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| EA201891377A1 (ru) | ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ | |
| AU2015267099A8 (en) | Use of eribulin in the treatment of cancer | |
| TW201713341A (en) | Compositions and methods of treating a neurodegenerative disease | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| MX388722B (es) | Compuestos para tratar el cancer de ovario. | |
| MX2023010501A (es) | Profarmacos de dantroleno y metodos de su uso. | |
| MX2019015212A (es) | Compuestos para el tratamiento del sarcoma. | |
| MX383254B (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| EA201892297A1 (ru) | Способы лечения холестатических и фибротических заболеваний | |
| PH12022551035A1 (en) | Siglec-9 ecd fusion molecules and methods of use thereof | |
| MX2023012415A (es) | Metodos de uso del dantroleno para tratar la exposicion a agente nervioso. | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| BR112019004791A2 (pt) | tratamento de esclerose múltipla com chs-131 | |
| MX2019007041A (es) | Metodos y composiciones para tratar la enfermedad de parkinson. | |
| ZA202103788B (en) | Use of dantrolene and dantrolene prodrugs to treat radiation exposure | |
| EA201800565A1 (ru) | Композиция для лечения заболеваний уха, содержащая (+)-азасетрон |